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pulmonary edema in dogs, and to compare LUS to other indicators of L‐CHF control. 
Animals Twenty‐five client‐owned dogs hospitalized for treatment of first‐onset L‐CHF. 
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Results From time of hospital admission to discharge (mean 19.6 hours), median number of LUS sites 
strongly positive for B‐lines (>3 B‐lines per site) decreased from 5 (range, 1‐8) to 1 (range, 0‐5; P < .001), 
and median total B‐line score decreased from 37 (range, 6‐74) to 5 (range, 0‐32; P = .002). Lung 
ultrasound indices remained improved at first recheck (P < .001). Number of strong positive sites 
correlated positively with respiratory rate (r = 0.52, P = .008) and TXR edema score (r = 0.51, P = .009) at 
hospital admission. Patterns of edema resolution differed between LUS and TXR, with cranial quadrants 
showing more significant reduction in B‐lines compared to TXR edema score (80% vs 29% reduction, 
respectively; P = .003). 
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Abstract
Background: Point-of-care lung ultrasound (LUS) is an effective tool to diagnose
left-sided congestive heart failure (L-CHF) in dogs via detection of ultrasound arti-
facts (B-lines) caused by increased lung water.
Hypothesis/Objectives: To determine whether LUS can be used to monitor resolu-
tion of cardiogenic pulmonary edema in dogs, and to compare LUS to other indicators
of L-CHF control.
Animals: Twenty-five client-owned dogs hospitalized for treatment of first-onset L-CHF.
Methods: Protocolized LUS, thoracic radiographs (TXR), and plasma N-terminal pro-
B-type natriuretic peptide were performed at hospital admission, hospital discharge,
and recheck examinations. Lung ultrasound findings were compared between
timepoints and to other clinical measures of L-CHF.
Results: From time of hospital admission to discharge (mean 19.6 hours), median
number of LUS sites strongly positive for B-lines (>3 B-lines per site) decreased from
5 (range, 1-8) to 1 (range, 0-5; P < .001), and median total B-line score decreased
from 37 (range, 6-74) to 5 (range, 0-32; P = .002). Lung ultrasound indices remained
improved at first recheck (P < .001). Number of strong positive sites correlated posi-
tively with respiratory rate (r = 0.52, P = .008) and TXR edema score (r = 0.51,
P = .009) at hospital admission. Patterns of edema resolution differed between LUS
and TXR, with cranial quadrants showing more significant reduction in B-lines com-
pared to TXR edema score (80% vs 29% reduction, respectively; P = .003).
Conclusions and Clinical Importance: Lung ultrasound could be a useful tool for
monitoring resolution of pulmonary edema in dogs with L-CHF.
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Abbreviations: DCM, dilated cardiomyopathy; HR, hazard ratio; L-CHF, left-sided congestive heart failure; LA, left atrium; LA : Ao, ratio of left atrial to aortic diameter; LUS, lung ultrasound;
MMVD, myxomatous mitral valve disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OR, odds ratio; TP, timepoints; TXR, thoracic radiographs.
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1 | INTRODUCTION
Left-sided congestive heart failure (L-CHF) in dogs typically manifests
as pulmonary edema from increased hydrostatic pressure within the
left atrium (LA) and pulmonary vasculature. Traditionally, assessment
of L-CHF in dogs relies on thoracic radiographs (TXR) to identify pul-
monary edema in dogs with compatible clinical signs and physical
examination findings.1 Although commonly utilized, TXR have disad-
vantages for detecting and monitoring L-CHF. First, TXR necessitate
recumbent positioning and removal from an oxygen chamber, which
can exacerbate hypoxemia and respiratory distress. Second, TXR can
be associated with relatively frequent misinterpretation (18% rate of
false positive L-CHF diagnosis in 1 study),2 particularly if radiographic
technique is suboptimal. Furthermore, repeated TXR can lead to
increased radiation exposure for animals and staff.
Point-of-care lung ultrasound (LUS) is an effective tool for the diag-
nosis of L-CHF in humans, dogs, and cats and can differentiate between
cardiogenic pulmonary edema and noncardiac causes of dyspnea or
cough with high sensitivity and specificity.2-8 In this setting, LUS has
demonstrated a similar or greater positive predictive value than N-
terminal pro-B-type natriuretic peptide (NT-proBNP) or TXR.4,8-12 Use
of LUS to detect L-CHF involves identification of ultrasound artifacts
termed B-lines.7 B-lines are discrete narrow-based vertical hyperechoic
artifacts extending from the lung surface to the far field without fading,
and moving synchronously with respiration.7,10,13 B-lines are caused by
the high impendence gradient of a fluid-air interface that occurs when
edema in the pulmonary interstitium and alveoli is adjacent to pulmo-
nary air. Isolated B-lines can occur in up to 31% of dogs with radio-
graphically normal lungs,14 while numerous multifocal B-lines are
reported in cardiogenic pulmonary edema,2-4,15 pneumonia,2 and pul-
monary contusions16 in dogs and cats.
Lung ultrasound has utility in serial monitoring of pulmonary edema
in humans with L-CHF, with B-lines decreasing over a number of hours
and resolving within days of diuretic treatment.17,18 Improvement in
B-lines also correlates well with other markers of L-CHF resolution,
including TXR and NT-proBNP.18 Although LUS shows promise as a
monitoring tool for pulmonary edema in humans, this has yet to be
investigated in dogs. The primary objective of our study was to investi-
gate the utility of LUS to monitor resolution of pulmonary edema in dogs
following a diagnosis of L-CHF. Secondary goals included: (a) to compare
LUS findings to other indicators of L-CHF resolution, including TXR,
respiratory rate, and NT-proBNP; (b) to assess patterns of edema resolu-
tion on LUS vs TXR; and (c) to evaluate the ability of LUS or other indices
to predict clinical outcome, including early L-CHF recurrence and cardiac
death. We hypothesized that LUS would be diagnostically useful in mon-
itoring clinical and radiographic resolution of L-CHF in dogs.
2 | MATERIALS AND METHODS
Study procedures were approved by the Institutional Animal Care and
Use Committees at the participating institutions. Informed owner con-
sent was obtained for each study dog.
Client-owned dogs presented to the Small Animal Emergency and
Critical Care Service or the Cardiology Service at the Iowa State Uni-
versity Lloyd Veterinary Medical Center and the North Carolina State
Veterinary Hospital were prospectively enrolled after diagnosis of
first-onset L-CHF. Diagnosis of L-CHF (initial episode and subsequent
recurrence, if applicable) was based on a combination of: (a) clinical
signs and physical examination findings consistent with L-CHF
(increased respiratory rate or effort, with or without cough or exercise
intolerance); (b) echocardiogram performed by a board-certified cardi-
ologist or cardiology resident confirming presence of severe myxoma-
tous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM);
(c) TXR demonstrating the presence of an interstitial or alveolar pul-
monary pattern consistent with cardiogenic pulmonary edema; and
(d) a positive clinical response (decreased respiratory rate) with furo-
semide diuresis. Additional inclusion criteria included completion of
the following diagnostic tests within 6 hours of hospital admission:
LUS performed by a trained investigator; 3-view TXR; and venous
blood sampling for plasma NT-proBNP. Dogs with moderate-to-
severe pleural effusion were excluded, as pressure atelectasis could
create B-lines independent of pulmonary pathology. Dogs that had
evidence of previous L-CHF or that were receiving furosemide at time
of initial presentation were excluded, as were dogs that were hospital-
ized for less than 6 hours.
Dogs received emergent and outpatient treatment for L-CHF
according to standard medical practices. Emergency treatments
included supplemental oxygen, sedatives, furosemide IV, and
pimobendan PO. Occasionally dobutamine, vasodilators (hydralazine
or nitroprusside), or antiarrhythmics (digoxin, diltiazem, lidocaine,
sotalol, or mexiletine) were provided. Outpatient medical treatment
usually included furosemide, pimobendan, an angiotensin-converting
enzyme inhibitor, and spironolactone PO, and occasionally included
adjunctive vasodilators (amlodipine) or antiarrhythmic medications at
the discretion of the attending clinician.
Clinically important timepoints (TP) were defined as initial presen-
tation for diagnosis of L-CHF (testing completed within 6 hours of
hospital presentation; TP1); hospital discharge (testing completed
within 2 hours of hospital discharge; TP2); first outpatient recheck
examination after hospital discharge (TP3); and subsequent recheck
examinations (TP4+). Dogs were deemed stable for hospital discharge
(TP2) when they were eupneic with respiratory rate <40 breaths per
minute when breathing room air. The period between recheck exami-
nations was determined by generalized recommendations of the cardi-
ology services of each institution and the clinical progression of the
individual dog. Physical examination, ECG, LUS, TXR, NT-proBNP, and
caregiver-completed cardiac quality-of-life19 were performed at each
TP. Respiratory rate was measured at the time of LUS, while other
physical examination findings were documented at the time of pre-
sentation. To prioritize dog stability at TP1, pharmacologic treatment
for L-CHF was permitted before imaging or between TXR and LUS at
the discretion of the clinician. Body temperature, heart rate, and the
quality-of-life questionnaire were not recorded at TP2.
All LUS examinations were performed by cardiologists or cardiol-
ogy residents trained in lung ultrasonography using compact portable
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ultrasound machines equipped with curvilinear probes (Iowa State
University: CX50 CompactXtreme Ultrasound [model 101855], Philips
Healthcare, Andover, Massachusetts; C8-5 Transducer [part #
FUS5124], Philips Healthcare, Andover, Massachusetts; North Caro-
lina State University: Fukuda Denshi Ultrasound [model UF-760AG,
Version 02], Tokyo, Japan; Fukuda Denshi Transducer [model FUT-
CA144-9P], Tokyo, Japan) utilizing standard settings (ultrasound fre-
quency 5-8 MHz; depth 4-6 cm).3 The same machine and settings
were used for serial examinations of the same dog. The technique for
small animal LUS (Vet BLUE) has been previously described.3,4,14,20
Briefly, images were obtained from four standardized acoustic win-
dows over each hemithorax with dogs standing or in sternal recum-
bency for a total of 8 LUS sites (right [R] vs left [L]; caudal [Cd],
perihilar [Ph], middle [Md], and cranial [Cr]). Three-second cine loops
were captured and archived from each site. Each site was evaluated
for the presence of B-lines in real time by the operator. If present, the
maximum number of B-lines within an intercostal space was recorded
as 0, 1, 2, 3, >3, or infinite. Infinite B-lines were recorded if numerous
coalescing B-lines could not be individually discerned. Sites with >3 or
infinite B-lines were scored as strong positive sites based on a con-
sensus panel for LUS in people.3,4,7,15 The total B-line score and the
total number of strong positive sites were summed and recorded for
each LUS examination, with >3 and infinite B-lines per intercostal
space recorded as 4 and 10 B-lines, respectively, for the purposes of
total B-line scoring. This scoring system was adopted from previous
studies in human and veterinary patients with a maximum potential
total B-line score of 80.4,6 At the time of LUS, a single right par-
asternal 2-dimensional short-axis image of the heart base was
obtained to assess left atrial size from the same point-of-care ultra-
sound unit, transducer, and body position (sternal or standing). A still
image optimizing the LA in diastole was used to measure the ratio of
the internal diameter of the left atrium to the diameter of the aorta
(LA : Ao), as has been previously described. 21
Three-view TXR were performed by the diagnostic imaging ser-
vice at each institution. Post hoc analysis was performed by a single
board-certified radiologist (J. L. F.) blinded to the LUS results. A modi-
fied Murray Lung Injury Score was used to evaluate the distribution
and severity of interstitial or alveolar infiltrates as previously
described in dogs.15,22 Briefly, the thorax from a dorsoventral view
was divided via a vertical line along the spine made from the thoracic
inlet through the middle of the thorax and a perpendicular line
through the carina, creating 4 quadrants (left cranial [Q1], left caudal
[Q2], right cranial [Q3], and right caudal [Q4]). Each quadrant was
scored 0 (no infiltrates), 1 (infiltrates affecting <25% of the quadrant),
2 (25%-50% of the quadrant affected), 3 (50%-75% of the quadrant
affected), or 4 (75%-100% of the quadrant affected). The sum of the
quadrants was recorded with a maximum potential TXR edema score
of 16. For direct comparison with LUS, Q1 included LCr + LMd, Q2
included LPh + LCd, Q3 included RCr + RMd, and Q4 included RPh
+ RCd LUS sites.
Venous blood samples were collected at each TP and plasma was
transported the same day to a reference laboratory for quantitative
NT-proBNP measurement (Cardiopet Canine proBNP test, IDEXX
Laboratories, Inc, Westbrook, Maine). Lead II ECGs were performed
and interpreted by cardiologists or cardiology residents; any rhythm
other than sinus rhythm or sinus tachycardia was defined as an
arrhythmia, including atrial fibrillation and ventricular or supraventric-
ular ectopy.
Final outcome (date and cause of death, or date of last follow-up
if alive) was recorded for all dogs at the end of the study period. Car-
diac death was defined as death or euthanasia secondary to clinical
signs suggestive of L-CHF or sudden death at home with no known
alternative noncardiac cause. Early recurrence of L-CHF was defined
as relapse of L-CHF within 90 days of TP1.
Statistical analyses were performed using 2 commercially available
software packages (GraphPad Prism 8, Graphpad Software, La Jolla,
California; MedCalc Version 17.6, MedCalc Software Ltd, Seoul, South
Korea). Normality of data was assessed using a combination of visual
inspection of histograms and D'Agostino Pearson testing. Categorical
data are reported as frequencies and proportions. Quantitative data are
reported as mean ± SD (normally distributed data) or median and range
(non-normally distributed data). For normally distributed continuous
data, paired t test or 1-way repeated measures analysis of variance with
Tukey's correction for multiple comparisons was used to compare data
between TPs or between dogs with or without early recurrence of L-
CHF. For non-normally distributed continuous data, Wilcoxon
matched-pairs signed rank test or Friedman test with Dunn's correction
for multiple comparison was used to assess differences between these
groups. Chi-square analysis was used to evaluate differences in cate-
gorical data. Correlations between variables at different TPs were per-
formed using Spearman analysis. Patterns of resolution of pulmonary
edema between lung regions were compared within and between LUS
and TXR using a combination of Student's t tests, Mann-Whitney log-
rank tests, and Chi-square analyses. For dogs experiencing relapse of L-
CHF at TP4+ visits, variables at TP4+ were compared to TP1 variables
for the same dog using parametric and nonparametric paired-rank ana-
lyses, with each recheck visit at TP4+ being considered as a separate
event. Univariate and multivariable logistic regression analysis was per-
formed to assess continuous and categorical variables for their utility in
predicting early recurrence of L-CHF; TP1, TP2, and TP3 variables were
assessed in independent models. Univariate and multivariable Cox
regression analysis was performed to evaluate TP3 variables predictive
for cardiac death. Variables significant in univariate regression analyses
subsequently were entered into a multivariable stepwise regression
analysis. Survival time between dogs that died as a result of cardiac dis-
ease versus dogs that died from other causes was compared with a log-
rank test. For all statistical tests, a value of P < .05 was considered
significant.
3 | RESULTS
3.1 | Study sample
Twenty-five client-owned dogs met inclusion criteria, with 20 dogs
enrolled at Iowa State University and 5 dogs from North Carolina
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State University. Sixteen dogs were males and 9 were females; 4 dogs
were sexually intact (3 males and 1 female). Sixteen breeds were rep-
resented, with Doberman Pinschers (n = 4) and Maltese (n = 3) being
most common. Causes of L-CHF included MMVD in 15/25 dogs
(60%) and DCM in 10 dogs. Clinical and physical examination data for
the study sample at TP1 to TP3 are shown in Table 1. One dog was
euthanized between TP2 and TP3 due to acute kidney injury.
3.2 | Lung ultrasound, TXR, and clinical variables at
TP1-3
Lung ultrasound was feasible in all dogs. Results for total B-line score
and number of strong positive sites for TP1-3 are shown in Table 1.
Median time between hospital presentation and TP1 LUS was 2.47
(range, 0.75-5.97) hours. Median time between TP1 LUS and TP2 LUS
was 19.6 (range, 6-116) hours, approximating the duration of hospital-
ization for initial diagnosis and treatment of L-CHF in this sample of
dogs. At least 1 strong positive LUS site (>3 B-lines per site) was pre-
sent in all dogs at TP1. Both total B-line score and the number of
strong positive sites were decreased at TP2 compared to TP1; median
percent reduction in total B-lines between TP1 and TP2 was 87%
(range, −25% to 100%), and median percent reduction in strong posi-
tive sites was 86% (range, 0%-100%). Figure 1 demonstrates improve-
ment in a single LUS site between TP1 and TP2 for a representative
dog. The first recheck examination (TP3) occurred a median of
12 days (range, 8-156) after hospital discharge. Lung ultrasound vari-
ables (total B-line score and number of strong positive sites) remained
lower at TP3 compared to TP1.
Thoracic radiograph results at TP1-3 are summarized in Table 1. The
median time from hospital admission to TP1 TXR was 2.23 (range,
0.5-6) hours. Fourteen (56%) dogs had TXR completed before LUS at TP1,
while the remaining 11 (44%) had LUS performed first; themedian absolute
time between imaging modalities at TP1 was 1.3 (range, 0.12-3.97) hours.
Nineteen (76%) dogs received at least 1 dose of parenteral furosemide
prior to any imaging studies, while 6 (24%) dogs received an additional dose
between imaging studies (3 of which had LUS performed first and 3 of
which had TXR performed first). Compared to TP1, TXR edema score
decreased at TP2 and TP3, with median reductions of 60% (range, −100%
to 100%) and 100% (range, −100% to 100%), respectively. There was no
difference between TXR edema scores at TP2 and TP3.
Timepoint 1-3 comparisons for physical examination findings,
plasma NT-proBNP, and quality-of-life scores are included in Table 1.
Significant changes in respiratory rate, body temperature, and heart
rate were appreciated between TP1 and TP3. Plasma NT-proBNP
concentration was higher at TP1 compared to TP2, but did not differ
between either TP2 and TP3 or TP1 and TP3. Except for 1 dog at
TP3, quality-of-life questionnaires were completed for all dogs at TP1
and TP3. Average scores were lower for TP3 than for TP1,
corresponding with improved perceived quality-of-life from prior to
hospitalization to first recheck examination postdischarge.
3.3 | Distribution and patterns of resolution of
pulmonary edema between TP1-2
Regional distribution of edema at TP1 differed between LUS and TXR,
as did the pattern of edema resolution between TP1-2. B-line
TABLE 1 Clinical data and diagnostic results at hospital presentation (TP1), hospital discharge (TP2), and first recheck examination (TP3) for









Number of dogs 25 25 24a — — —
Body temperature (F) 101.0 ± 1.2 — 102.1 (99.3-102.7) — — .035*
Respiratory rate (breaths/
min)
69 ± 27 36 ± 11 36 ± 11 <.001* .73 <.001*
Heart rate (beats/min) 164 ± 27 — 137 ± 27 — — <.001*
LUS total B-line score 39.9 ± 20.3 4 (0-32) 0 (0-2) .002* .015* <.001*
LUS total strong positive
sites
5.1 ± 2.04 1 (0-5) 0 (0-1) <.001* .23 <.001*
TXR edema score 8.4 ± 4.25 3.5 ± 3 0 (0-8) .008* .27 <.001*







Quality-of-life score 38 ± 18 — 15 ± 9 — — <.001*
Note: Data are expressed as mean ± SD for normally distributed data and as median (range) for non-normally distributed data. Significant differences
(P < .05) between timepoints are denoted with an asterisk (*).
Abbreviations: LUS, lung ultrasound; NT-proBNP, N-terminal B-type natriuretic peptide; TXR, thoracic radiographs.
aOne dog was euthanized between hospital discharge and first recheck due to complications of acute kidney injury.
4 MURPHY ET AL.
distribution was relatively uniform across all LUS sites at both TP1
and TP2; neither the distribution of B-lines nor the distribution of
strong positive sites varied between the left and right hemithoraces at
TP1 (P = .27 and P = .77, respectively) or TP2 (P = .76 and P = .84,
respectively). On LUS, a reduction in number of B-lines and strong
positive sites was observed for all 8 individual LUS sites between TP1
and TP2 (see Figures 2 and 3). In contrast, at TP1, TXR results
suggested more severe edema within the right lungs, with higher
median pulmonary edema scores in the right quadrants (Q3 + Q4; 2.5,
range 0-4) compared to left (Q1 + Q2; 1.5, range 0-4) (P = .02). This
F IGURE 1 Still B-mode lung ultrasound (LUS) images from the left middle site of a single study dog at the time of initial diagnosis of left-
sided congestive heart failure (A) compared to hospital discharge after aggressive treatment of congestive heart failure (B). In figure (A), infinite
coalescing B-lines are seen between rib shadows within each intercostal space, while (B) demonstrates resolution of B-lines and return of normal
LUS A-line artifacts
F IGURE 2 Number of B-lines at
each of 8 individual lung ultrasound
(LUS) sites, compared between
hospital presentation (TP1) and
hospital discharge (TP2), in 25 dogs
with left-sided congestive heart
failure. Median and interquartile
range presented in boxplots, with
whiskers indicating range. Cd, caudal;
Cr, cranial; L, left; Md, middle; Ph,
perihilar; R, right
F IGURE 3 Percent of dogs with
strong positive lung ultrasound (LUS)
findings (>3 B-lines) at each of
8 individual LUS sites, compared between
hospital presentation (TP1) and hospital
discharge (TP2), in 25 dogs with left-sided
congestive heart failure. Cd, caudal; Cr,
cranial; L, left; Md, middle; Ph, perihilar; R,
right
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TXR discrepancy did not persist at TP2, with no difference in pulmo-
nary edema distribution between right and left hemithoraces (P = .05),
though a reduction in edema scores at TP2 was observed for both
right (P < .001) and left (P < .001) hemithoraces compared to TP1.
The percent change between TP1 and TP2 in total LUS B-lines
and TXR edema scores were compared between modalities for each
quadrant (see Figure 4). The right cranial quadrant (Q3) differed
between modalities in percent change between TPs, demonstrating
an 80% reduction in B-lines and only a 25% reduction in TXR edema
score (P = .01). The left cranial quadrant (Q1) showed an 80% reduc-
tion in B-lines and 33% TXR reduction in edema score, which was not
statistically significant (P = .09). Caudal quadrants (Q2 and Q4) did not
differ between LUS and TXR in terms of percent change between TP1
and TP2 (P = .75 and .41, respectively). Cranial and caudal quadrants
were then grouped and analyzed together. In cranial quadrants (Q1
+ Q3), B-line score reduced more than TXR edema score (80% vs 29%
reduction, respectively; P = .003), while the degree of resolution of
the caudal quadrants (Q2 + Q4) was similar between LUS and TXR
(93% vs 75% reduction, P = .46).
3.4 | Correlations between markers of L-CHF
control at TP1-3
Both LUS indices (total B-line score and number of strong positive
sites) correlated with other markers of L-CHF at time of initial diagno-
sis. Total B-lines and strong positive sites correlated positively with
respiratory rate (r = 0.54, P = .006; r = 0.52, P = .008) and TXR edema
score (r = 0.46, P = .02; r = 0.51, P = .009) at TP1. Percent reduction
in total B-lines or strong positive sites from TP1-2 or TP1-3 did not
correlate with percent reduction of any other measured clinical
indices of L-CHF control during those same periods. In contrast, per-
cent reduction in TXR edema score from TP1-2 correlated positively
with percent reduction in respiratory rate over the same time frame
(r = 0.57; P = .004), but was not correlated with percent reduction in
other clinical indices of L-CHF control. Neither plasma NT-proBNP
nor percent change in NTproBNP correlated with other L-CHF
markers at any TP.
3.5 | Control vs recurrence of L-CHF at TP4+
Recurrence of L-CHF was diagnosed in 7 dogs at 8 of 31 total hospital
visits for the entire study sample at TP4 and beyond (TP4+). Clinical
variables at TP4+ were compared between visits when recurrent L-
CHF was diagnosed vs visits when L-CHF was considered controlled.
At-home median respiratory rates measured before the visit were sig-
nificantly higher for dogs found to have uncontrolled L-CHF
(36 breaths/min; range, 28-52) compared to those with controlled L-
CHF (26 breaths/min; range, 16-32; P = .02); although in-hospital
respiratory rates were not different between groups (P = .42). Both
LUS indices detected higher measures of pulmonary edema in recur-
rent vs controlled L-CHF (P < .001 for both total B-line score and
number of strong positive sites). Plasma NT-proBNP was not different
between instances of recurrent L-CHF and controlled L-CHF at TP4
+ (P = .24).
For dogs that experienced recurrence of L-CHF at TP4+, certain
clinical variables at these TP4+ relapses differed compared to the
same dog's characteristics at original TP1 presentation for L-CHF.
Compared to TP1, recurrent episodes of L-CHF had lower total B-line
scores and number of strong positive LUS sites (P < .001 for both),
lower TXR edema scores (P = .003), and lower respiratory rates
(P = .03), but higher LA : Ao values (P = .034). Heart rate (P = .22),
plasma NT-proBNP (P = .22), and quality-of-life score (P = .19) did not
differ between first-time L-CHF (TP1) and recurrent L-CHF (TP4+).
3.6 | Predictors of early recurrence and cardiac
death
Dogs were divided into 2 groups to assess for clinical variables that
could predict outcome. Group 1 consisted of dogs that had a docu-
mented recurrence of L-CHF or cardiac death within 90 days of L-
CHF diagnosis, while group 2 consisted of dogs that survived to
90 days without experiencing L-CHF relapse. Twenty-three dogs
were included in this analysis, excluding the dog euthanized for
noncardiac disease between TP2-3 and a dog lost to follow-up before
90 days postdiagnosis. Group 1 consisted of 6 dogs while group 2
was comprised of the remaining 17 dogs. Clinical and imaging vari-
ables from TP1-3 were tested for differences between groups; indi-
vidual variables (with associated TP) that differed significantly
between group 1 and group 2 are shown in Table 2. The only signifi-
cant predictors of negative outcome at 90 days in regression analysis
among TP1 variables was higher TXR edema score at TP1 (odds ratio
F IGURE 4 Percent reduction in B-lines on lung ultrasound (LUS)
and edema score on thoracic radiographs (TXR) between hospital
presentation (TP1) and hospital discharge (TP2) in 25 dogs with left-
sided congestive heart failure. Results are separated by anatomic
quadrant. Median and interquartile range presented in boxplots, with
whiskers indicating range.
Note: 1 measurement each for LUS Q1, LUS Q3, and LUS Q4 are
below the depicted −100% y-axis limit. Q1, cranial quadrant; Q2, left
caudal quadrant; Q3, right cranial quadrant; Q4, right caudal quadrant
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[OR] = 1.39, 95% confidence interval [CI] = 1.003-1.92; P = .05) and
among TP3 variables was presence of arrhythmia (OR = 15, 95%
CI = 1.14-198, P = .04).
At time of manuscript writing, 14 of 25 dogs had died, including
10 by cardiac death and 4 by noncardiac death. Median survival time
for these deceased dogs was 165 (range, 3-759) days, and did not dif-
fer between cardiac (159 days [range, 11-759 days]) vs noncardiac
(168 days [range, 3-210 days]) causes of death (P = .64). Median fol-
low-up time for dogs still alive at the end of the study was 353 (range,
12-571) days. The only study variables that differed between dogs
that experienced cardiac death (n = 10) and those that died of
noncardiac causes or were alive at the end of the study (n = 15) were
respiratory rate at TP1 (P = .02), TXR edema score at TP1 (P = .006),
and percent reduction in respiratory rate from TP1 to TP2 (P = .03).
Univariate Cox regression analysis of TP3 parameters found that the
percentage reduction of strong positive sites between TP1 and TP3
(hazard ratio [HR] = 0.907, 95% CI = 0.847-0.972, P = .006) and
higher TXR edema score at TP3 (HR = 1.365, 95% CI = 1.061-1.756,
P = .02) were significant predictors of cardiac death. Only TXR edema
score at TP3 remained a predictor of cardiac death on multivariable
analysis (HR = 1.365, 95% CI = 1.061-1.756, P = .02).
4 | DISCUSSION
Lung ultrasound indices in dogs, including total B-lines and the num-
ber of strong positive sites, improved from initial diagnosis of L-CHF
to hospital discharge with continued improvement at first recheck.
The most significant reduction in B-lines occurred between the first
2 TP (median 20 hours apart), when aggressive medical treatment for
L-CHF control with injectable furosemide was utilized. This LUS
improvement was similar to that seen in a study of acute
decompensated heart failure in 70 people, which demonstrated reso-
lution of B-lines after 4.2 days of medical treatment for L-CHF.18 Both
LUS indices (total B-line score and total number of strong positive
LUS sites) performed well for the purpose of monitoring edema reso-
lution in our study (87% and 86% reduction between TP1 and TP2,
respectively), with no clear clinical advantage of tracking 1 over the
other.
Median number of B-lines (5) and strong positive sites (1) per dog
at hospital discharge, though significantly improved compared to diag-
nosis, remained higher than reported for dogs with radiographically
normal lungs.14 In a study of 98 normal dogs, 11% of dogs were found
to have B-lines on LUS, with the vast majority having only 1 B-line
detected at a single LUS site. This difference suggests that despite
being eupneic, dogs in our study likely maintained some degree of
residual pulmonary edema at time of hospital discharge. By the time
of first recheck examination (median 12 days later), LUS results were
indistinguishable from normal dogs (median 0 B-lines). Lung ultra-
sound indices then increased during relapses of L-CHF at subsequent
recheck examinations (TP4+). Overall, the results of our study suggest
that B-line artifacts improve quickly and track with TXR and clinician-
assessed clinical improvement (or relapse) of pulmonary edema in
dogs with L-CHF. In addition to being an accurate method of monitor-
ing L-CHF, LUS was also technically feasible at all TP and could be
performed with dogs in their preferred body position through a small
portal in a supplemental oxygen chamber, if needed. These results
suggest that LUS could be an effective and practical tool for monitor-
ing L-CHF, associated with decreased radiation exposure and poten-
tially lower cost compared to repeated TXR.
Our study also provides information about the distribution and
patterns of resolution of pulmonary edema in dogs assessed by LUS
compared to TXR. Spatial distribution of pulmonary edema at diagno-
sis (TP1) differed between LUS and TXR; LUS typically detected dif-
fuse and symmetric edema with B-lines in all sites, while TXR edema
was more severe within the right lungs. These results are consistent
with previous reports3,15 suggesting that in dogs with L-CHF, LUS
typically detects B-lines diffusely (all quadrants within each
TABLE 2 Clinical findings, imaging results, and other diagnostic findings that differed significantly between dogs that experienced recurrence
of left-sided congestive heart failure or cardiac death within 90 days of diagnosis (group 1) compared to those that survived to 90 days without
experiencing a relapse of L-CHF (group 2)
Variable Group 1 Group 2 P value
Number of dogs 6 17 —
TXR edema score at TP1 11 (8-16) 7 (0-16) .02
Arrhythmia at TP1 (n, %) 5/6 (83%) 4/17 (24%) .02
NT-proBNP at TP2 (pmol/L) 3100 (1472-10 000) 1441 (397-10 000) .034
Reduction in NT-proBNP from TP1 to TP2 (%) 3.3% (−4.3% to 50.4%) 59.9% (−89.1% to 87.3%) .049
Arrhythmia at TP3 (n, %) 3/5 (60%) 3/17 (17.6%) .046
Reduction in strong positive LUS sites from TP1 to
TP3 (%)
93.8% (57.1%-100%) 100% (80%-100%) .031
Note: All clinical and imaging variables at TP1-3 were evaluated for between-group differences; only those variables at specific TP listed in the table were
significantly different between group 1 and group 2. Data are expressed as mean ± SD for normally distributed data, median (range) for non-normally
distributed data, and number (percent) for categorical data.
Abbreviations: L-CHF, left-sided congestive heart failure; LUS, lung ultrasound; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TP, timepoints;
TXR, thoracic radiographs.
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hemithorax) and is more likely to detect edema in the cranial lung
regions compared to TXR. As with LUS, TXR edema scores improved
from initial L-CHF diagnosis to hospital discharge in our study, with a
median 60% reduction between TP1 and TP2. The discrepancy
between 60% reduction in TXR-detected edema and 86% reduction
in LUS-detected edema might reflect mathematical differences in the
scoring systems utilized for each imaging modality, or could be due to
differences in the ability of LUS vs TXR to detect edema located
peripherally vs centrally within a lung lobe. It is impossible to assess
relative accuracy of these imaging modalities without more invasive
tests (such as extravascular lung water) for comparison.23,24 Patterns
of edema resolution between diagnosis and hospital discharge for
dogs with L-CHF have not been previously published, and also dif-
fered between imaging modalities in our study. Results showed uni-
form resolution of edema from TP1 to TP2 detected by LUS for each
quadrant (between 75% and 95% reduction) and for cranial (80%) vs
caudal (93%) quadrants when grouped. In comparison, the cranial
edema detected by TXR reduced from TP1 to TP2 by only 29%, while
edema in caudal quadrants reduced to a similar degree as LUS-
detected edema (75%). This discrepancy might suggest that LUS is
superior to TXR at detecting presence or absence of edema within the
cranial and middle lung quadrants, compared to perihilar and caudal
quadrants where both modalities identified edema similarly with simi-
lar resolution patterns.
Improvement in LUS indices and TXR-assessed edema tracked
with improvement of in-hospital respiratory rates between hospital
presentation and discharge in our study. The correlation between
respiratory rate and LUS indices was not statistically significant, likely
because number of B-lines and strong positive sites decreased in a
nearly “all-or-none” categorical fashion compared to a more measured
decrease in respiratory rate. Owner-monitored respiratory rate at
home was higher for recheck examinations when dogs were
experiencing a relapse of L-CHF compared to visits when L-CHF was
controlled. These results are consistent with a previous canine study
that found decreases in respiratory rate between time of L-CHF diag-
nosis and recheck examination 5 to 14 days later25 and suggested that
owner-assessed at-home respiratory rates were the best indicator of
L-CHF control. Interestingly, in our study, in-hospital respiratory rate
at recheck examinations (TP4+) did not differ based on whether L-
CHF was controlled. These data suggest that respiratory rates mea-
sured at home are more accurate indicators of recurrent cardiogenic
pulmonary edema compared to respiratory rates measured in hospital.
Similar findings have been reported in previous studies,25-27 likely due
to clinic-associated anxiety causing mild elevation in respiratory rates
in dogs without active L-CHF. In-hospital respiratory rates (along with
LUS and TXR imaging markers of L-CHF) were significantly lower dur-
ing recurrence of pulmonary edema at TP4+ compared to initial diag-
nosis of L-CHF, likely as a result of either ongoing outpatient medical
treatment buffering the severity of recurrent pulmonary edema, or
improved owner education allowing identification of more subtle
changes in respiratory pattern.
Plasma NT-proBNP concentrations decreased between presenta-
tion and discharge from the hospital (median 19.6 hours); however,
NT-proBNP concentrations at the first recheck examination (median
12 days) had increased to levels similar to initial diagnosis. This finding
differed from a previous study of canine L-CHF that found decreases
in NT-proBNP between time of L-CHF diagnosis and recheck exami-
nation 5 to 14 days later.25 This might reflect progressive cardiac wall
stress between hospital discharge and first recheck associated with
diuretic de-escalation from inpatient parenteral dosing to outpatient
oral furosemide. Furthermore, NT-proBNP at subsequent rechecks
(TP4+) did not differ based on presence or absence of recurrent pul-
monary edema. Potential explanations include wide intraindividual
variability and breed differences in circulating NT-proBNP concentra-
tions, or progressive reduction in glomerular filtration rate over time
leading to reduced NTproBNP clearance.28-30 Overall, these findings
suggest that NT-proBNP might not be an as effective for assessment
of clinical L-CHF control (absence of pulmonary edema) compared to
TXR or LUS.
Lung ultrasound indices, along with other clinical and diagnostic
markers of L-CHF at TP1-3, were evaluated as potential predictors of
early recurrence of pulmonary edema. A semi-arbitrary cutoff of
90 days was established to define early recurrence of L-CHF for this
purpose based on the typically recommended recheck schedule for
dogs diagnosed with L-CHF at the study institutions (every
90-120 days). Among LUS variables analyzed, only the percent reduc-
tion in strong positive sites between L-CHF diagnosis (TP1) and first
recheck (TP3) differed between dogs with or without early L-CHF
recurrence, and this variable did not remain predictive of L-CHF
relapse in regression analysis. Plasma NT-proBNP at hospital dis-
charge was also higher in dogs who experienced early cardiac death
or recurrence of heart failure, though similarly was not significant in
univariate regression. Only TXR edema scores at TP1 and arrhythmia
presence at TP3 were significant predictors of early L-CHF relapse in
univariate analysis. The association between negative outcome and
arrhythmias at TP3 is unsurprising, since arrhythmias such as atrial
fibrillation31,32 and ventricular ectopy33 are known negative prognos-
tic indicators in canine heart disease. The association between TXR
edema score, but not LUS variables, at initial presentation with subse-
quent L-CHF relapse was interesting. This disparity might have
occurred because dogs with only mild to moderate pulmonary edema
on TXR usually had infinite B-lines on LUS; therefore, dogs were more
likely to achieve the maximum possible quantitative scores on LUS
compared to TXR. Assuming that severity of an initial L-CHF episode
is indeed predictive of recurrence of L-CHF, these findings could sug-
gest that compared to TXR, LUS might be more sensitive for detection
of pulmonary edema but less able to discriminate severity of L-CHF.
The small number of dogs that developed early recurrence of L-CHF
in our study, and the dichotomy of selecting a single timeframe after
diagnosis to define early L-CHF recurrence, might have limited our
ability to recognize trends in this sample of dogs.
There are several limitations of our study, including the small
number of dogs experiencing relapse of L-CHF or cardiac death during
the study period. Lung ultrasound was performed and interpreted in
real time by multiple different cardiologists and cardiology residents
with previous training in LUS. Results might have been different with
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inexperienced operators or if images were interpreted offline by a sin-
gle observer, although previous studies have demonstrated excellent
interobserver agreement for detection of B-lines between trained
novice and expert individuals.3 Operators were not systematically
blinded to TXR findings, which could have introduced bias in B-line
scores. The study sample included dogs with 2 acquired cardiac dis-
eases with different anticipated prognoses,33-38 which might limit the
importance of the results of our survival analyses. Despite setting time
constraints in our inclusion criteria, there remained variation in timing
between imaging studies at TP1 (6-hour window) and TP2 (2-hour
window), along with differences in the amount and timing of diuretic
treatment in proximity to these studies. This variability could feasibly
have affected our results; in particular, diuretic treatment adminis-
tered between TXR and LUS at TP1 could affect correlation between
modalities. Additionally, certain TP were clinician-dependent and
somewhat owner- and schedule-dependent. For example, the time of
hospital discharge (TP2) was sometimes later than medically necessary
due to the client's or cardiology service's schedule, and increased time
for diuresis could affect imaging results at that TP. Finally, while con-
current LUS and TXR performed similarly in monitoring resolution and
recurrence of L-CHF in this sample of dogs, further study is required
to determine if the clinical utility of LUS would persist in the absence
of TXR.
In our study, LUS showed potential utility for monitoring resolu-
tion and recurrence of L-CHF in dogs, tracking well with respiratory
rate and radiographic edema scores and outperforming NT-proBNP.
Lung ultrasound could be considered as a practical alternative to
repeated TXR for monitoring of L-CHF in dogs.
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